Get the Stockscreener App
10.05
28.52%
2.23
After Hours:
15.65
5.60
+55.72%
Ventyx Biosciences Inc stock is traded at $10.05, with a volume of 2.70M.
It is up +28.52% in the last 24 hours and up +15.25% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$7.82
Open:
$7.9
24h Volume:
2.70M
Relative Volume:
0.69
Market Cap:
$717.15M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-3.0455
EPS:
-3.3
Net Cash Flow:
$-167.04M
1W Performance:
+14.86%
1M Performance:
+15.25%
6M Performance:
+383.17%
1Y Performance:
+315.29%
1-Day Range:
$7.08
$25.00
1-Week Range:
$7.08
$25.00
52-Week Range:
$0.783
$25.00
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(760) 407-6511
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
10.05 | 558.02M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - GlobeNewswire Inc.
Ventyx Biosciences (NASDAQ:VTYX) Shares Down 6.1%Time to Sell? - MarketBeat
Investors Purchase Large Volume of Call Options on Ventyx Biosciences (NASDAQ:VTYX) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Ventyx Biosciences, Inc. (VTYX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc.VTYX - PR Newswire
Ventyx Biosciences (NASDAQ:VTYX) Trading Up 2.8%Here's What Happened - MarketBeat
Ventyx Biosciences (NASDAQ:VTYX) Shares Down 3.4%Time to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ventyx Biosciences, Inc. (VTYX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Will Ventyx Biosciences Inc. stock benefit from green energy trendsBollinger Bands Signals & Affordable Market Insights - bollywoodhelpline.com
Bronstein, Gewirtz & Grossman, LLC Encourages Ventyx Biosciences, Inc. (VTYX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ventyx Biosciences, Inc. (VTYX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Ventyx Biosciences, Inc. (VTYX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ventyx Biosciences, Inc. (VTYX) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ventyx Biosciences, Inc. (VTYX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Will Ventyx Biosciences Inc. stock return to pre crisis levelsMarket Sentiment Summary & Free Fast Entry Momentum Trade Alerts - Улправда
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ventyx Biosciences, Inc. (VTYX) And Encourages Stockholders to Connect - ACCESS Newswire
One Ventyx Biosciences Insider Raised Their Stake In The Previous Year - Yahoo Finance
Analysts Bullish as Ventyx Biosciences (VTYX) Advances Its Clinical and Strategic Initiatives - Insider Monkey
VTYX DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Ventyx Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 30 Deadline in Securities Class Action – VTYX - Macau Business
Will Ventyx Biosciences Inc. stock split attract more investorsWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - bolumsonucanavari.com
Is Ventyx Biosciences Inc. stock a safe haven assetJuly 2025 Spike Watch & Low Volatility Stock Suggestions - Улправда
Ventyx Biosciences (NASDAQ:VTYX) Insider John Nuss Sells 12,675 Shares - MarketBeat
Insider Selling: Ventyx Biosciences (NASDAQ:VTYX) CEO Sells 47,345 Shares of Stock - MarketBeat
Ventyx Biosciences Executives Conduct Share Transactions - TradingView — Track All Markets
Ventyx Biosciences (NASDAQ:VTYX) Trading 13.5% HigherStill a Buy? - MarketBeat
Ventyx Biosciences, Inc. (VTYX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Officer Nuss Files To Sell 12,675 Of Ventyx Biosciences Inc [VTYX] - TradingView — Track All Markets
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ventyx Biosciences, Inc. (VTYX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Ventyx Biosciences, Inc. (VTYX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Ventyx Biosciences, Inc. $VTYX Shares Sold by Redmile Group LLC - MarketBeat
Ongoing Investigation: Ventyx Biosciences, Inc. (VTYX) May Have Misled ShareholdersLevi & Korsinsky Investigates - ACCESS Newswire
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 11% Over the Past Week - 富途牛牛
VTYX Investor Notice: Levi & Korsinsky Investigates Ventyx Biosciences, Inc. for Securities Law Violations - ACCESS Newswire
Ventyx shares drop after pushing back Phase 2 interim results to early 2026 - MSN
Piper Sandler Sticks to Its Buy Rating for Ventyx Biosciences (VTYX) - The Globe and Mail
Ventyx Biosciences (NASDAQ:VTYX) Trading 12.3% HigherHere's Why - MarketBeat
Affinity Asset Advisors LLC Invests $9.71 Million in Ventyx Biosciences, Inc. $VTYX - MarketBeat
Wells Fargo Remains a Buy on Ventyx Biosciences (VTYX) - The Globe and Mail
Ventyx Biosciences (NASDAQ:VTYX) Shares Gap DownShould You Sell? - MarketBeat
Ventyx Biosciences, Inc. $VTYX Shares Sold by Sio Capital Management LLC - MarketBeat
Ventyx strengthens advisory board, expands phase 2 pericarditis study By Investing.com - Investing.com Nigeria
Ventyx Biosciences Announces Appointment to Advisory Board - marketscreener.com
Ventyx provides clinical and corporate updates - marketscreener.com
Ventyx Provides Clinical And Corporate Updates - TradingView
Ventyx Biosciences Expands Phase 2 Recurrent Pericarditis Study Into Canada, EU, UK - marketscreener.com
Ventyx stock falls after delaying trial data to Q1 2026 By Investing.com - Investing.com Canada
Ventyx strengthens advisory board, expands phase 2 pericarditis study - Investing.com
Ventyx Provides Clinical and Corporate Updates - The Manila Times
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ventyx Biosciences Inc Stock (VTYX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohan Raju | CEO AND PRESIDENT |
Dec 18 '25 |
Sale |
7.72 |
47,345 |
365,461 |
2,372,863 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 17 '25 |
Option Exercise |
0.00 |
34,930 |
0 |
502,156 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 18 '25 |
Sale |
7.72 |
12,675 |
97,840 |
489,481 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):